FBR & Co Reaffirms Outperform Rating for RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “outperform” rating restated by research analysts at FBR & Co in a report released on Wednesday. They presently have a $36.00 target price on the stock. FBR & Co’s price objective suggests a potential upside of 156.59% from the company’s previous close.
RDHL has been the topic of a number of other reports. Zacks Investment Research upgraded shares of RedHill Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, August 26th. HC Wainwright set a $33.00 target price on shares of RedHill Biopharma and gave the company a “buy” rating in a research note on Friday, October 7th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. RedHill Biopharma presently has a consensus rating of “Buy” and an average price target of $26.20.
RedHill Biopharma (NASDAQ:RDHL) traded up 1.07% during mid-day trading on Wednesday, hitting $14.18. 11,635 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $14.63 and its 200-day moving average price is $12.81. The stock’s market cap is $180.57 million. RedHill Biopharma has a 12 month low of $8.10 and a 12 month high of $16.54.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/fbr-co-reaffirms-outperform-rating-for-redhill-biopharma-ltd-rdhl.html
RedHill Biopharma (NASDAQ:RDHL) last released its earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.52. Equities analysts expect that RedHill Biopharma will post ($2.06) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the company. Van ECK Associates Corp boosted its stake in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in RedHill Biopharma during the second quarter valued at about $142,000. Royal Bank of Canada boosted its stake in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares in the last quarter. Finally, Ingalls & Snyder LLC purchased a new stake in RedHill Biopharma during the second quarter valued at about $451,000. Institutional investors and hedge funds own 15.30% of the company’s stock.
RedHill Biopharma Company Profile
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.